代謝疾患治療薬の世界市場:高血圧、肥満、高コレステロール血症、ライソゾーム病...市場調査レポートについてご紹介

【英文タイトル】Global Metabolic Disorders Therapeutics Market 2016-2020

▼当市場調査レポートの詳細内容確認、お問い合わせ及びご購入申込は下記ページでお願いします。▼マーケットレポート

【レポートの概要(一部)】

PART 01: Executive summary
• Highlights

PART 02: Scope of the report
• Market overview
• Top-vendor offerings

PART 03: Market research methodology
• Research methodology
• Economic indicators

PART 04: Introduction
• Key market highlights

PART 05: Pipeline portfolio
• Pipeline portfolio: Global diabetes drugs market
• Pipeline portfolio: Global hyperphosphatemia drugs market
• Pipeline portfolio: Global anti-obesity drugs market

PART 06: Market landscape
• Market overview
• Market size and forecast
• Five forces analysis

PART 07: Market segmentation by type of disease
• Diabetes
• Obesity
• Hypercholesterolemia
• Lysosomal storage diseases

PART 08: Global diabetes drugs market
• Market overview
• Global type 1 diabetes market
• Global type 2 diabetes drugs market
• Vendors in global diabetes drugs market

PART 09: Global hypercholesterolemia drugs market
• Market overview
• Vendors in global hypercholesterolemia drugs market

PART 10: Global lysosomal storage diseases market
• Market overview
• Vendors in global lysosomal storage disorders drugs market

PART 11: Global anti-obesity drugs market
• Market overview
• Vendors in global anti-obesity drugs market

PART 12: Geographical segmentation
• Global metabolic disorders therapeutics market by geography 2015-2020
• Metabolic disorders therapeutics market in Americas
• Metabolic disorders therapeutics market in EMEA
• Metabolic disorders therapeutics market in APAC

PART 13: Market drivers
• Patient assistance programs
• Special regulatory designations for rare diseases
• Increase in academia-industry collaborations for drug development

PART 14: Impact of drivers

PART 15: Market challenges
• Low compliance and adherence rates
• High cost of therapies
• Complex storage conditions and distribution policies for insulin

PART 16: Impact of drivers and challenges

PART 17: Market trends
• Focus on oral insulin therapies
• Strong and diversified pipeline portfolio
• Strategic collaborations and acquisitions

PART 18: Vendor landscape
• Competitive scenario
• Other prominent vendors

PART 19: Key vendor analysis
• Novo Nordisk
• Sanof
• Merck
• AstraZeneca
• Eli Lilly

PART 20: Appendix
• List of abbreviations

PART 21: Explore Technavio

[List of Exhibits]

Exhibit 01: Product offerings
Exhibit 02: Key buying criteria and customer segments for metabolic disorder drugsKey buying criteria for metabolic disorders drugs 2015
Exhibit 03: Impact of key customer segments on market 2015
Exhibit 04: Global metabolic disorders therapeutic market snapshot: Developed and emerging markets 2015
Exhibit 05: Global metabolic disorders therapeutics market 2015-2020 ($ billions)
Exhibit 06: Opportunity analysis: Global metabolic disorders therapeutics market
Exhibit 07: Global metabolic disorders therapeutics market: Growth cycle analysis
Exhibit 08: Five forces analysis
Exhibit 09: Global metabolic disorders therapeutics market by type of disease
Exhibit 10: Global metabolic disorders therapeutics market by type (2015-2020)
Exhibit 11: Global metabolic disorders therapeutics market n growth lifecycle analysis
Exhibit 12: Top selling diabetes drugs based on sales 2015 ($ billions)
Exhibit 13: Market share of global diabetes drugs in global pharmaceutical market 2015
Exhibit 14: Global diabetes drugs market 2015-2020 ($ billions)
Exhibit 15: Global type 1 diabetes market 2015-2020 ($ billions)
Exhibit 16: Global type 2 diabetes drugs market 2015-2020 ($ billions)
Exhibit 17: Market share analysis of vendors in global diabetes drugs market
Exhibit 18: Revenues from the sales of top five products in global diabetes drugs market 2013-2015 ($ billions)
Exhibit 19: Revenues from the sales of top five products in hypercholesterolemia drugs market 2013-2015 ($ billions)
Exhibit 20: Market dynamics of hypercholesterolemia drugs
Exhibit 21: Percentage share of hypercholesterolemia drugs by drug class 2015
Exhibit 22: Global hypercholesterolemia drugs market 2015-2020 ($ billions)
Exhibit 23: Market share analysis of global hypercholesterolemia drugs market 2015
Exhibit 24: Products offered by major vendors in global hypercholesterolemia drugs market
Exhibit 25: Global lysosomal storage diseases drugs market 2015-2020 ($ billions)
Exhibit 26: Key events in treatment of lysosomal storage diseases
Exhibit 27: Products offered by major vendors in global lysosomal storage disorders drugs market
Exhibit 28: Global anti-obesity drugs market 2015-2020 ($ millions)
Exhibit 29: Products offered by major vendors in global anti-obesity drugs market
Exhibit 30: Global metabolic disorders therapeutics market by geography 2015-2020
Exhibit 31: Global metabolic disorder therapeutics market by geography 2015 and 2020
Exhibit 32: Global metabolic disorder therapeutics market by geography 2015-2020 ($ billions)
Exhibit 33: Global share of metabolic disorder therapeutics market by geography 2015
Exhibit 34: Global share of various metabolic disorder therapeutics market by geography based on disease type 2015
Exhibit 35: Global metabolic disorders therapeutics market by region: Market growth lifecycle analysis 2015
Exhibit 36: Metabolic disorder therapeutics market in Americas 2015-2020 ($ billions)
Exhibit 37: Prevalence of obesity in various countries in Europe 2025
Exhibit 38: Metabolic disorders therapeutics market in EMEA 2015-2020 ($ billions)
Exhibit 39: Metabolic disorder therapeutics market in APAC 2015-2020 ($ billions)
Exhibit 40: Prevalence of diabetes in selected countries in APAC 2007 and 2025
Exhibit 41: Few metabolic disorder drugs with patient assistance programs
Exhibit 42: Impact of drivers
Exhibit 43: Impact of drivers and challenges
Exhibit 44: Oral insulin pipeline portfolio
Exhibit 45: Some investigational molecules for metabolic disorders and their mechanisms
Exhibit 46: Key vendors ranking 2015
Exhibit 47: Geographical presence of key vendors
Exhibit 48: Competitive scenario of global metabolic disorders therapeutics market vendors 2015-2020
Exhibit 49: Novo Nordisk: Profile
Exhibit 50: Novo Nordisk: Strength analysis
Exhibit 51: Novo Nordisk: Growth strategy matrix
Exhibit 52: Novo Nordisk: Growth opportunity assessment
Exhibit 53: Novo Nordisk: Business segmentation by revenue 2015
Exhibit 54: Novo Nordisk: Key products in diabetes and obesity care
Exhibit 55: Novo Nordisk: YoY growth and revenue generated from net product sales of human insulins 2012-2015 ($ billions)
Exhibit 56: Novo Nordisk: YoY growth and revenue generated from net product sales of Levemir 2012-2015 ($ billions)
Exhibit 57: Novo Nordisk: YoY growth and revenue of NovoRapid/ NovoLog 2012-2015 ($ billions)
Exhibit 58: Novo Nordisk: YoY growth and revenue of NovoMix/NovoLog Mix 2012-2015 ($ billions)
Exhibit 59: Novo Nordisk: Revenue generated from net product sales of new-generation insulins 2013-2015 ($ millions)
Exhibit 60: Novo Nordisk: YoY growth and revenue of Victoza 2012-2015 ($ billions)
Exhibit 61: Novo Nordisk: YoY growth and revenue of Novonorm, Prandin, and Prandimet 2012-2014 ($ billions)
Exhibit 62: Sanofi: Business segmentation by revenue 2015
Exhibit 63: Sanofi: Profile
Exhibit 64: Sanofi: Strength analysis
Exhibit 65: Sanofi growth strategy matrix
Exhibit 66: Sanofi: Growth opportunity assessment
Exhibit 67: Key product offerings in diabetes market ($ billions)
Exhibit 68: Sanofi: YoY revenue and growth rate of Lantus 2012-2015 ($ billions)
Exhibit 69: Sanofi: YoY revenue and growth rate of Amaryl 2012-2015 ($ billions)
Exhibit 70: Sanofi: YoY revenue and growth rate of Apidra 2012-2015 ($ billions)
Exhibit 71: Sanofi: YoY revenue and growth rate of Insuman 2012-2015 ($ billions)
Exhibit 72: Sanofi: YoY revenue and growth rate of Lyxumia 2013-2015 ($ millions)
Exhibit 73: Sanofi: Revenues of lysosomal storage diseases drugs of Genzyme, 2015
Exhibit 74: Merck: Strength profile
Exhibit 75: Merck: Strength analysis
Exhibit 76: Merck: Growth strategy matrix
Exhibit 77: Merck: Opportunity assessment
Exhibit 78: Top selling diabetes drugs in 2015
Exhibit 79: Merck: Diabetes segmentation by revenue 2015
Exhibit 80: Merck: YoY growth and revenue of Janumet 2012-2015 ($ billions)
Exhibit 81: Merck: YoY growth and revenue of Januvia 2012-2015 ($ billions)
Exhibit 82: Merck: YoY revenue and growth rate of Zetia 2013-2015 ($ billions)
Exhibit 83: Merck: YoY revenue and growth rate of Vytorin 2013-2015 ($ billions)
Exhibit 84: Merck: YoY revenue and growth rate of Zocor 2013-2015 ($ millions)
Exhibit 85: AstraZeneca: Profile
Exhibit 86: AstraZeneca: Strength analysis
Exhibit 87: AstraZeneca: Growth strategy matrix
Exhibit 88: AstraZeneca: Opportunity assessment
Exhibit 89: Top selling diabetes drugs in 2015 ($ billions)
Exhibit 90: AstraZeneca: Byetta YoY growth and revenues 2012-2015 ($ billions)
Exhibit 91: Astrazeneca: Byetta YoY growth rate and revenues in the US ($ billions)
Exhibit 92: AstraZeneca: Bydureon YoY revenues and growth rate 2012-2015 ($ billions)
Exhibit 93: AstraZeneca: Onglyza YoY revenue and growth rate 2012-2015 ($ billions)
Exhibit 94: AstraZeneca: YoY revenue and growth rate of Crestor 2013-2015 ($ billions)
Exhibit 95: AstraZeneca: Geographical segmentation of Crestor 2015 by revenue
Exhibit 96: Eli Lilly: Profile
Exhibit 97: Eli Lilly: Strength analysis
Exhibit 98: Eli Lilly growth strategy matrix
Exhibit 99: Eli Lilly: Opportunity assessment
Exhibit 100: Top selling diabetic drugs 2015 ($ billions)
Exhibit 101: Eli Lilly: YoY revenue and growth rate of Humalog 2012-2015 ($ billions)
Exhibit 102: Eli Lilly: YoY revenue and growth rate of Humulin 2012-2015 ($ billions)
Exhibit 103: Eli Lilly: YoY revenue and growth rate of Tradjenta 2012-2015 ($ billions)
Exhibit 104: Eli Lilly: YoY revenue of Trylicity 2014-2015 ($ millions)


【レポート販売概要】

■ タイトル:代謝疾患治療薬の世界市場:高血圧、肥満、高コレステロール血症、ライソゾーム病
■ 英文:Global Metabolic Disorders Therapeutics Market 2016-2020
■ 発行日:2016年9月27日
■ 調査会社:Technavio
■ 商品コード:IRTNTR10218
■ 調査対象地域:グローバル
※当サイトは世界の市場調査レポート紹介サイトです。市場規模、市場動向、市場予測など、多様な分析データを含むグローバル調査レポートをご案内致します。日本国内を含むアジア太平洋、中国、ヨーロッパ、アメリカ、北米、中南米、中東、アフリカ地域などにおける、製品、サービス、技術、企業(メーカー、ベンダー)、市場シェア、市場環境など多様な項目に対応致します。当サイトでご紹介するレポートは「市場調査レポート販売サイトのMarketReport.jp」でお問い合わせ及びご購入可能です。